OnDemand WTP Pricing Research

Legislature passes multiple health policy bills in final week – State of Reform | State of Reform

Prescription Drug Price Transparency

The Prescription Drug Price Transparency Act (HB 4005) also passed this session. The bill requires prescription drug manufactures to annually report prices of prescription drugs and the developing and marketing costs to the Department of Consumer and Business Services. It also establishes the Task Force on the Fair Pricing of Prescription Drugs to develop a strategy to create transparency for drug prices across the entire supply chain.

The bill passed out of the House 46-14 and the Senate 24-4. The Oregon Bioscience Association, PhRMA, MolecularMD, and DesignMedix testified in opposition, often citing increased complexity, confusion, and costs for pharmaceutical manufacturing and research companies.

Eric Lohnes, PhRMA’s senior director of state policy, testified against the bill:

“This bill provides an extremely narrow, over simplified, and distorted view of what is a complicated issue, with a complex supply chain, and various actors. This bill is silent on the value of medicine, and does not address some of the most impactful actors in the supply chain, namely PBMs and Insurance Carriers. Most importantly, this bill does nothing to help patients or save money for patients at the points of sale.”

Read complete article here:

Legislature passes multiple health policy bills in final week – State of Reform | State of Reform.